The therapeutic effects and mechanisms of action of resveratrol on polycystic ovary syndrome: A comprehensive systematic review of clinical, animal and in vitro studies

Karimi, Arash; Tutunchi, Helda; Naeini, Fatemeh; Vajdi, Mahdi; Mobasseri, Majid; Najafipour, Farzad

doi:10.1111/1440-1681.13698

Cited by 10 publications

(4 citation statements)

References 78 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…OS in patients with PCOS may be associated with several diseases [ 34 , 35 ]. A few antioxidants can ameliorate PCOS through reducing OS, such as Tempol [ 36 ], Kelulut honey [ 37 ], Standardised Aronia melanocarpa [ 38 ], astaxanthin [ 39 ], resveratrol [ 40 ], and N-acetyl cysteine [ 41 ]. Besides, silibinin [ 42 ] and vitamin E supplementation [ 43 ] as well as melatonin and/or magnesium supplementation [ 44 ] also ameliorate PCOS by reducing the level of OS.…”

Section: Discussionmentioning

confidence: 99%

Evidence for causal effects of polycystic ovary syndrome on oxidative stress: a two-sample mendelian randomisation study

2023

BMC Med Genomics

View full text Add to dashboard Cite

Background Polycystic ovary syndrome (PCOS) is often accompanied by increased oxidative stress levels; however, it is still unclear whether PCOS itself is causally related to oxidative stress (OS), whether OS can increase the occurrence of PCOS, and which characteristics of PCOS increase OS levels. Therefore, this study explored the causal relationship between PCOS, its characteristics, and OS. Methods Two-sample bidirectional and two-sample Mendelian randomisation studies were performed based on publicly available statistics from genome-wide association studies. PCOS; its characteristics, such as testosterone, low-density lipoprotein, high-density lipoprotein; and 11 major OS markers (superoxide dismutase, glutathione S-transferase, glutathione peroxidase, catalase, uric acid, zinc, tocopherol, ascorbic acid, retinol, albumin, and total bilirubin), were studied. The main analytical method used was inverse variance weighting (IVW). Pleiotropy was evaluated using the Mendelian randomisation-Egger intercept. Q and P values were used to assess heterogeneity. Results There was no causal relationship between PCOS and the OS indices (all P > 0.05). There was a causal relationship between the OS index, ascorbate level, and PCOS (IVW, odds ratio: 2.112, 95% confidence interval: 1.257–3.549, P = 0.005). In addition, there was a causal relationship between testosterone, low-density lipoprotein, high-density lipoprotein, sex hormone-binding globulin, body mass index, triacylglycerol, age at menarche, and most OS indices according to the IVW method. The F statistics showed that there was no weak instrumental variable. A sensitivity analysis was performed using the leave-one-out method. No pleiotropy was observed. The results were robust, and the conclusions were reliable. Conclusions This study showed for the first time that there was no causal relationship between PCOS and OS. However, there was a causal relationship between the OS index, ascorbate level, and PCOS. It revealed that PCOS itself could not increase OS, and the increase in OS in PCOS was related to other potential factors, such as testosterone, low-density lipoprotein, high-density lipoprotein, sex hormone-binding globulin, body mass index, triacylglycerol, and age at menarche.

show abstract

Section: Discussionmentioning

confidence: 99%

Evidence for causal effects of polycystic ovary syndrome on oxidative stress: a two-sample mendelian randomisation study

2023

BMC Med Genomics

View full text Add to dashboard Cite

show abstract

“…In a recent systematic review [ 93 •], which considered both in vitro studies and animal or human models of PCOS, it has been highlighted that resveratrol supplementation could be effective in reducing IR, improving dyslipidemia, ovarian morphology as well as anthropometric indices, regulating reproductive hormones and reducing inflammation and oxidative stress, influencing biological pathways.…”

Section: Adjuvant Nutraceutical and Pharmacological Treatmentmentioning

confidence: 99%

Hypothalamic-Ovarian axis and Adiposity Relationship in Polycystic Ovary Syndrome: Physiopathology and Therapeutic Options for the Management of Metabolic and Inflammatory Aspects

Lonardo,

Cacciapuoti,

Guida

et al. 2024

Curr Obes Rep

View full text Add to dashboard Cite

Purpose of Review The goal of the present review is to address the main adiposity-related alterations in Polycystic Ovary Syndrome (PCOS) focusing on hypothalamic-pituitary-ovarian (H-P-O) axis and to provide an overview of nutraceutical and pharmacological therapeutic strategies. Recent Findings Female reproduction is a complex and delicate interplay between neuroendocrine signals involving the H-P-O axis. Elements that disrupt the balance of these interactions can lead to metabolic and reproductive disorders, such as PCOS. This disorder includes menstrual, metabolic, and biochemical abnormalities as well as hyperandrogenism, oligo-anovulatory menstrual cycles, insulin resistance, and hyperleptinemia which share an inflammatory state with other chronic diseases. Moreover, as in a self-feeding cycle, high androgen levels in PCOS lead to visceral fat deposition, resulting in insulin resistance and hyperinsulinemia, further stimulating ovarian and adrenal androgen production. In fact, regardless of age and BMI, women with PCOS have more adipose tissue and less lean mass than healthy women. Excessive adiposity, especially visceral adiposity, is capable of affecting female reproduction through direct mechanisms compromising the luteal phase, and indirect mechanisms as metabolic alterations able to affect the function of the H-P-O axis. Summary The intricate crosstalk between adiposity, inflammatory status and H-P-O axis function contributes to the main adiposity-related alterations in PCOS, and alongside currently available hormonal treatments, nutraceutical and pharmacological therapeutic strategies can be exploited to treat these alterations, in order to enable a more comprehensive synergistic and tailored treatment.

show abstract

“…In DHEAinduced PCOS rats, it was testedat the dose of 20 mg/kg/day, and the study results reveal that it significantly decreases LH/FSH, TNFα, atretic follicles, Graafian follicles, and maintains folliculogenesis. 15 Rhamnocitrin is a flavonoid present in several medicinal herbs, has demonstrated anti-inflammatory, anti-apoptotic, and antioxidant activities. In letrozole-induced PCOS rats, rhamnocitrin was given at the dose of 5 mg/kg/day and it was reported that it ameliorates PCOS by reducing body weight, ovarian weight, improves ovarian structure and reduces fibrosis.…”

Section: Phytoconstituents In Pcosmentioning

confidence: 99%

Exploring the therapeutic potential of phytoconstituents in treatment of polycystic ovarian syndrome: An study

Premkumar

Priyanka

C.N

et al. 2023

IJPP

View full text Add to dashboard Cite

Polycystic ovary syndrome (PCOS) is a prevalent condition among women of reproductive age, characterised by hyperinsulinemia, hyperandrogenism, menstrual irregularities, and long-term metabolic disturbances. At present, the conventional approach to managing PCOS involves implementing lifestyle changes, administering pharmacological interventions, and performing surgical procedures. Nevertheless, these therapies do not exhibit promising outcomes for the comprehensive eradication of it. Consequently, natural sources have been regarded as a highly esteemed means of medication and aid in enhancing and regulating PCOS conditions. The current study was designed to conduct a screening of various phytoconstituents with a focus on their potential interaction with androgenic targets (1E3G & 2PIV), estrogenic receptors (1U3S), and insulin receptors (3EKK). An assessment was conducted on a compilation of phytoconstituents documented in PCOS with the aim of forecasting drug-like characteristics through an methodology. Thirteen phytoconstituents were selected for the study, namely apigenin, berberine, erdosteine, colchicine, diacerin, mogroside V, naringenin, quercetin, resveratrol, rhamnocitrin, silibinin, tanshinone IIA, and troxerutin. The phytoconstituents were subjected to molecular docking studies using AutoDock Vina to investigate their binding interactions with proposed targets. Additionally, in silico prediction of the toxicity of these phytoconstituents was conducted. The phytoconstituents that were chosen exhibited favourable pharmacokinetic characteristics for oral bioavailability and drug-likeness, as determined by Lipinski's rule of five. As per the docking results, it was observed that four compounds, namely Apigenin, Tanshinone IIA, Naringenin, and Berberine, exhibited significant binding interactions with the allosteric site residues of the targets. The identified phytoconstituents that underwent screening exhibit potential as prospective candidates for subsequent development. However, it is imperative to validate the findings through in vitro and in vivo investigations.

show abstract

The therapeutic effects and mechanisms of action of resveratrol on polycystic ovary syndrome: A comprehensive systematic review of clinical, animal and in vitro studies

Cited by 10 publications

References 78 publications

Evidence for causal effects of polycystic ovary syndrome on oxidative stress: a two-sample mendelian randomisation study

Evidence for causal effects of polycystic ovary syndrome on oxidative stress: a two-sample mendelian randomisation study

Hypothalamic-Ovarian axis and Adiposity Relationship in Polycystic Ovary Syndrome: Physiopathology and Therapeutic Options for the Management of Metabolic and Inflammatory Aspects

Exploring the therapeutic potential of phytoconstituents in treatment of polycystic ovarian syndrome: An study

Contact Info

Product

Resources

About